Real Challenges. Real Solutions.
Precision therapies for genetically defined diseases
Who We Are

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.

Opportunity for Impact
Millions of people around the world are living with a genetically defined disease.
Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases.

For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.

Advancing Best-in-Class
Precision Therapies
At Cogent, we start with the end in mind – with the goal of delivering meaningful therapies that improve human health. We focus on diseases where the cause is well understood and is directly linked to a genetic mutation, providing a path forward to develop novel precision therapies.
Explore
Discovering
New Solutions
We have built a world-class discovery organization in Boulder, Colorado, focused on pioneering best-in-class, small molecule therapeutics to improve upon existing drugs with clear limitations and safety concerns, with the goal of creating new breakthroughs for diseases where others have been unable to find adequate solutions.
Explore
Our People,
Our Promise
Cogent is driven by the patients we serve and committed to the opportunity to deliver novel precision therapies to patients with unmet medical needs. We are a Company of people who are passionate and dedicated to turning the promises of our therapies into reality in order to transform the lives of patients.
Explore
Latest News
November 28, 2022
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of
November 14, 2022
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in phase to be presented at CTOS 2022 Phase 2 APEX trial in Advanced Systemic Mastocytosis (AdvSM);
November 9, 2022
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in the following upcoming investor
November 3, 2022
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
Company to Host Virtual Investor Event on Monday, December 12 WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming
Scroll to Top